HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gilles Salles Selected Research

L-Lactate Dehydrogenase (Lactate Dehydrogenase)

1/2020International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
1/2016Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.
1/2013CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
9/2007Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gilles Salles Research Topics

Disease

96Neoplasms (Cancer)
05/2024 - 02/2003
81Lymphoma (Lymphomas)
12/2023 - 01/2002
81Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
11/2023 - 07/2006
66Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
04/2024 - 01/2002
40Non-Hodgkin Lymphoma (Lymphosarcoma)
02/2023 - 01/2002
34B-Cell Lymphoma (Lymphoma, B Cell)
04/2024 - 03/2005
28Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
03/2024 - 10/2003
20Disease Progression
08/2023 - 05/2004
16Hodgkin Disease (Hodgkin's Disease)
10/2021 - 01/2002
14B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
08/2022 - 04/2004
12Hematologic Neoplasms (Hematological Malignancy)
04/2024 - 06/2005
12Infections
01/2020 - 03/2005
11Neutropenia
12/2021 - 05/2013
10Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
04/2024 - 01/2012
10Multiple Myeloma
04/2024 - 07/2004
8Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
07/2019 - 02/2003
8Anemia
08/2017 - 03/2005
7Lymphoproliferative Disorders (Lymphoproliferative Disorder)
02/2017 - 03/2005
5Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
05/2024 - 03/2013
5Cytokine Release Syndrome
05/2024 - 01/2019
5Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
02/2021 - 10/2014
5Thrombocytopenia (Thrombopenia)
08/2017 - 03/2013
4Cytopenia
10/2023 - 06/2002
4T-Cell Lymphoma (Lymphoma, T Cell)
01/2023 - 12/2006
4Fatigue
01/2020 - 03/2013
4Leukemia
12/2018 - 10/2014
3Inflammation (Inflammations)
04/2024 - 10/2019
3Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
12/2019 - 11/2014
3Febrile Neutropenia
01/2019 - 06/2015
3Necrosis
01/2019 - 05/2016

Drug/Important Bio-Agent (IBA)

101Rituximab (Mabthera)FDA Link
11/2023 - 01/2002
23Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2023 - 01/2002
21Lenalidomide (CC 5013)FDA Link
12/2023 - 12/2010
19Prednisone (Sone)FDA LinkGeneric
12/2023 - 01/2002
19Doxorubicin (Adriamycin)FDA LinkGeneric
12/2023 - 01/2002
18Vincristine (Oncovin)FDA LinkGeneric
12/2023 - 01/2002
18Monoclonal AntibodiesIBA
01/2022 - 01/2002
17Biomarkers (Surrogate Marker)IBA
05/2024 - 03/2007
17Chimeric Antigen ReceptorsIBA
05/2024 - 01/2019
17obinutuzumabIBA
08/2022 - 05/2012
13ibrutinibIBA
11/2023 - 01/2016
12tafasitamabIBA
12/2023 - 01/2020
10Agammaglobulinaemia Tyrosine KinaseIBA
03/2024 - 01/2016
9DNA (Deoxyribonucleic Acid)IBA
03/2024 - 01/2012
9polatuzumab vedotinIBA
12/2023 - 06/2015
9Cytarabine (Cytosar-U)FDA LinkGeneric
01/2023 - 07/2015
9tisagenlecleucelIBA
11/2022 - 01/2019
8Bendamustine HydrochlorideFDA Link
11/2023 - 08/2016
8CytokinesIBA
12/2021 - 05/2004
8Proteins (Proteins, Gene)FDA Link
06/2021 - 01/2002
7Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/2024 - 10/2002
7GemcitabineFDA Link
01/2023 - 11/2013
6Interleukin-10 (Interleukin 10)IBA
05/2024 - 05/2004
6AntibodiesIBA
10/2023 - 07/2016
6AntigensIBA
01/2020 - 01/2002
5Dexamethasone (Maxidex)FDA LinkGeneric
01/2023 - 12/2010
5InterferonsIBA
01/2022 - 10/2006
5Etoposide (VP 16)FDA LinkGeneric
01/2022 - 07/2013
5idelalisibIBA
12/2021 - 01/2017
4Immunoconjugates (Immunoconjugate)IBA
04/2024 - 06/2015
4copanlisibIBA
01/2024 - 01/2020
4Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
12/2023 - 10/2016
4Immunoglobulins (Immunoglobulin)IBA
10/2023 - 02/2002
4Asparaginase (Elspar)FDA Link
01/2023 - 08/2012
4fludarabineIBA
01/2022 - 09/2017
4axicabtagene ciloleucelIBA
01/2022 - 11/2020
4tazemetostatIBA
06/2021 - 01/2020
4Melphalan (Alkeran)FDA LinkGeneric
01/2021 - 12/2010
4L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2020 - 09/2007
4HLA Antigens (Human Leukocyte Antigens)IBA
01/2018 - 10/2002
3brexucabtagene autoleucelIBA
03/2024 - 01/2022
3Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
01/2024 - 12/2017
3Dihydrotachysterol (AT 10)IBA
12/2023 - 10/2019
3Biosimilar PharmaceuticalsIBA
02/2023 - 05/2015
3Methotrexate (Mexate)FDA LinkGeneric
01/2023 - 08/2012
3Cytotoxins (Cytolysins)IBA
01/2022 - 07/2019
3BI 836826IBA
02/2021 - 10/2020
3Immunomodulating AgentsIBA
01/2020 - 09/2013
3Inosine Triphosphate (ITP)IBA
12/2019 - 11/2014
3AnthracyclinesIBA
05/2018 - 11/2015
3CreatinineIBA
08/2016 - 04/2016
3Telomerase (Telomerase Reverse Transcriptase)IBA
01/2016 - 12/2009
2Brentuximab VedotinIBA
05/2024 - 01/2018
2Heme (Haem)IBA
03/2024 - 10/2023

Therapy/Procedure

97Therapeutics
05/2024 - 01/2002
53Drug Therapy (Chemotherapy)
12/2023 - 01/2002
27Stem Cell Transplantation
01/2023 - 01/2002
8Transplantation
01/2023 - 04/2006
8Radiotherapy
01/2023 - 11/2007
7Salvage Therapy
05/2024 - 01/2002
7Aftercare (After-Treatment)
12/2023 - 12/2008
7Hematopoietic Stem Cell Transplantation
01/2020 - 07/2013
6Bone Marrow Transplantation (Transplantation, Bone Marrow)
08/2019 - 12/2017
5Splenectomy
01/2016 - 06/2002
4Cell Transplantation
12/2017 - 12/2017
3Immunotherapy
08/2023 - 07/2017
3Chemoradiotherapy
01/2023 - 08/2016
3Autologous Transplantation
08/2019 - 08/2007
3Ligation
11/2017 - 04/2015
3Injections
06/2017 - 10/2014